Tags : BioArctic’s

Pharma

AbbVie Exercises its Option to License Agreement for BioArctic’s Alpha-Synuclein

Shots: BioArctic to get $755M as total deal value (with upfront previously paid) and $50M milestone payments in addition to royalties on sales In 2016, AbbVie and BioArctic ($80M upfront) entered into a global collaboration to develop & commercialize BioArctic’s Alpha-Synuclein Ab Platform to treat Parkinson Disease BAN0805, a leading BioArctic’s Alpha-Synuclein Ab indicated for […]Read More